Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
As the hemodialysis population continues to rise in Korea, the heavy socioeconomic burden of imported dialyzers has become a growing concern. To address this issue, a new polyethersulfone (PES)-based dialyzer was developed domestically. The Synoflux® Series, a newly developed dialyzer, was evaluated for its clinical efficacy and safety compared with an existing dialyzer.
This multicenter, randomized, crossover, open-label study enrolled 25 patients on thrice-weekly hemodialysis. Participants received either Synoflux followed by ELISIO or vice versa, each for 6 weeks. The primary endpoint was urea reduction ratio (URR) at week 6. Secondary endpoints included small- (BUN, creatinine, phosphorus, potassium) and middle-molecule (β2-microglobulin, myoglobin, cystatin C, prolactin, α1-microglobulin, vitamin B12, interleukin-6) removal ratios, laboratory parameters, and safety outcomes such as serum albumin preservation, complement activation, and adverse events.
Twenty-four patients completed the study. Synoflux was non-inferior to ELISIO in URR (70.4% vs. 71.2%, mean difference –0.8%, 95% CI –2.4 to 0.8). Small-molecule clearance was similar between groups. Synoflux achieved significantly greater cystatin C removal (27.6% vs. 26.6%, p=0.032) and showed relatively higher removal of myoglobin and prolactin. Albumin loss was lower with Synoflux (–3.7%) compared with ELISIO (–6.1%), with no clinically significant hypoalbuminemia observed. Complement activation patterns indicated immunologic stability, and adverse events were comparable across groups.
Synoflux® Series demonstrated non-inferior dialysis adequacy and safety compared with ELISIO® Series, with potential advantages in middle-molecule clearance and albumin preservation. These findings support Synoflux as a safe and effective domestically manufactured dialyzer.
